ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,356.61
-0.71%
Dow Jones
39,850.03
-0.06%
Gold vs US Dollar
2,407.645
-0.57%
Brent Oil
81.645
-0.97%
Bitcoin
69,483.06
-0.92%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Abliva Ab (0QDU)

  7. Abliva Ab (0QDU) News

Abliva Ab (0QDU)

Abliva Ab
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0QDU
DateTimeSourceHeadlineSymbolCompany
19/02/202008:03PR Newswire (US)NeuroVive Pharmaceutical AB Year End Report January - December 2019LSE:0QDUAbliva Ab
19/02/202008:01PR Newswire (US)NeuroVive Pharmaceutical AB Year End Report January - December 2019LSE:0QDUAbliva Ab
20/12/201914:44PR Newswire (US)NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b StudyLSE:0QDUAbliva Ab
20/12/201914:40PR Newswire (US)NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b StudyLSE:0QDUAbliva Ab
16/12/201910:21PR Newswire (US)NeuroVive Announces Settlement in Dispute With CicloMulsion AGLSE:0QDUAbliva Ab
16/12/201910:19PR Newswire (US)NeuroVive Announces Settlement in Dispute With CicloMulsion AGLSE:0QDUAbliva Ab
20/11/201908:04PR Newswire (US)NeuroVive Pharmaceutical AB Interim Report January - September 2019LSE:0QDUAbliva Ab
20/11/201907:58PR Newswire (US)NeuroVive Pharmaceutical AB Interim Report January - September 2019LSE:0QDUAbliva Ab
21/08/201907:55PR Newswire (US)NeuroVive Pharmaceutical AB Interim Report January - June 2019LSE:0QDUAbliva Ab
21/08/201907:52PR Newswire (US)NeuroVive Pharmaceutical AB Interim Report January - June 2019LSE:0QDUAbliva Ab
20/08/201912:23PR Newswire (US)Save the Date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019LSE:0QDUAbliva Ab
27/07/201912:38PR Newswire (US)NeuroVive's NeuroSTAT Project Receives FDA Fast Track DesignationLSE:0QDUAbliva Ab
27/07/201912:35PR Newswire (US)NeuroVive's NeuroSTAT Project Receives FDA Fast Track DesignationLSE:0QDUAbliva Ab
04/07/201913:46PR Newswire (US)NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical StudyLSE:0QDUAbliva Ab
04/07/201913:45PR Newswire (US)NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical StudyLSE:0QDUAbliva Ab
21/05/201907:45PR Newswire (US)NeuroVive Pharmaceutical AB Interim Report January - March 2019LSE:0QDUAbliva Ab
10/05/201907:48PR Newswire (US)NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDALSE:0QDUAbliva Ab
10/05/201907:46PR Newswire (US)NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDALSE:0QDUAbliva Ab
25/03/201909:48PR Newswire (US)NeuroVive Pharmaceutical AB Publishes 2018 Annual ReportLSE:0QDUAbliva Ab
25/03/201909:43PR Newswire (US)NeuroVive Pharmaceutical AB Publishes 2018 Annual ReportLSE:0QDUAbliva Ab
07/03/201908:07PR Newswire (US)NeuroVive Receives SEK 28.2 Million in a Directed New Share IssueLSE:0QDUAbliva Ab
21/02/201907:52PR Newswire (US)NeuroVive Enters Commercial Partnership With Oroboros Instruments on Mitochondrial Medicine Research CompoundsLSE:0QDUAbliva Ab
15/11/201811:25PR Newswire (US)NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial DisordersLSE:0QDUAbliva Ab
15/11/201811:21PR Newswire (US)NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial DisordersLSE:0QDUAbliva Ab
31/10/201808:07PR Newswire (US)NeuroVive Today Announces That the Subscription Period for Warrants of Series 2018:1 Will Begin on Thursday, November 1LSE:0QDUAbliva Ab
04/10/201807:50PR Newswire (US)NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBILSE:0QDUAbliva Ab
04/10/201807:45PR Newswire (US)NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBILSE:0QDUAbliva Ab
11/12/201710:41PR Newswire (US)NeuroVive Reports Promising Progress in its Clinical Project for Genetic Mitochondrial Diseases, KL1333LSE:0QDUAbliva Ab
11/12/201710:38PR Newswire (US)NeuroVive Reports Promising Progress in its Clinical Project for Genetic Mitochondrial Diseases, KL1333LSE:0QDUAbliva Ab
 Showing the most relevant articles for your search:LSE:0QDU

Your Recent History

LSE
POLX
Polarean Imaging
LSE
VAST
Vast Resources
LSE
ZED
Zenova
LSE
POS
Plexus
LSE
PHE
Powerhouse Energy
LSE
TERN
Tern
LSE
SCLP
Scancell
LSE
AAZ
Anglo Asian Mining
LSE
LLOY
Lloyds Banking
LSE
KEFI
Kefi Gold And Copper
LSE
GGP
Greatland Gold
LSE
AGL
Angle
LSE
RKH
Rockhopper Exploration
LSE
PHNX
Phoenix
LSE
GKP
Gulf Keystone Petroleum
LSE
CYAN
Cyanconnode
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved